NCT06659705View on ClinicalTrials.gov

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 30, 2029

Study Completion Date

January 30, 2030

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
DRUG

68Ga-FAPI-46 for PET / CT scan and 177Lu-EB-FAPI for therapy

Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.

Trial Locations (1)

92210

Institut Curie -site Saint-Cloud, Saint-Cloud

All Listed Sponsors
lead

Institut Curie

OTHER